phrykt

Alterity Therapeutics Ltd (ATHE): who owns it and who trades it

As of Oct 30, 2026, ATHE insiders reported 1 purchase worth $23.8K in the last 12 months. The largest buyer was Peter Ashley Marks (Director), with $23.8K.

Latest filing Oct 30, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, ATHE insiders reported $23.8K of open-market purchases and $0 of sales.

Purchases, 12 months
$23.8K
1 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Aug 31, 2026
Filed Sep 8, 2026

Purchases and sales by month

$23.8K$23.8KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 31, 2026Peter Ashley MarksDirectorPurchase47,620$0.50$23.8KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Peter Ashley MarksDirector$23.8K–Aug 31, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ATHE short interest

Low short interest. Less than 0.1% of ATHE shares are sold short. Over the last 12 reports the number of shares short went up 206%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 24,614 ATHE shares were sold short, 0.0% of the shares outstanding, down 36.1% from the report before. At the average daily volume of 25,353 shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

0.01%Jun 30Oct 300.02%

Days to cover

1.0May 15Oct 303.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202624,6140.01%-36%25,3531.0
Oct 15, 202638,5160.02%+48%32,8211.2
Sep 30, 202626,1070.01%+2%12,0372.2
Sep 15, 202625,6600.01%-18%19,9461.3
Aug 31, 202631,4520.01%+27%22,8831.4
Aug 14, 202624,7630.01%+17%7,6833.2
Jul 31, 202621,0940.01%-45%10,7882.0
Jul 15, 202638,0370.02%-2%17,9832.1
Jun 30, 202638,9800.02%-28%33,1811.2
Jun 15, 202654,009–+486%148,3191.0
May 29, 20269,216–+14%21,8171.0
May 15, 20268,051–-42%28,2121.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Questions about Alterity Therapeutics Ltd (ATHE) stock

Are ATHE insiders buying or selling?

In the last 12 months, ATHE insiders reported 1 open-market purchase worth $23.8K and no sales. The latest trade was on Aug 31, 2026. See every trade.

What is the short interest in ATHE?

As of Oct 30, 2026, 24,614 ATHE shares were sold short, 0.0% of the shares outstanding, down 36.1% from the report before. At the average daily volume of 25,353 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.